Join Wilson Sonsini partner Eva Yin on May 13, 2026, as she and fellow panelists participate in a virtual briefing on the intersection of AI and HealthTech at the FDA. The webinar—co-sponsored by Wilson Sonsini, HSBC Innovation Banking, and Healthcare Innovation Catalysts—will offer practical and real-time insights in four areas: the FDA's framework for AI health tech, regulated health tech in practice, legal risk in the gray zone, and the global road ahead.
To register for the webinar, please visit the registration site.
Heidi Haslip
hhaslip@wsgr.com
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.